Due to apparent “deficiencies” in trial data, the FDA has rejected a request to approve Acadia Pharmaceutical’s application for the repurposing of Parkinson’s drug…
As part of our LiveTalk series, Being Patient spoke with dementia care expert Teepa Snow about strategies for caregivers to manage the symptoms of…
Now under review, the drug pimavanserin may become the first FDA-approved treatment for dementia-related psychosis. Roughly 2.4 million Americans experience symptoms of dementia-related psychosis,…
Phase III trials for experimental dementia-related psychosis treatment pimavanserin draw interest at AAIC; FDA begins consideration of the drug approval. As many as half…
SAN DIEGO — A highly anticipated Alzheimer’s conference opened here last night with reports about a powerful new drug for treating dementia-related delusions. ACADIA…